Drug-Induced Phospholipidosis

Annual Reports in Medicinal Chemistry

Volumn 46, Issue , 2011, Pages 419-430

  Bernstein, Peter R ^a   Ciaccio, Paul ^b   Morelli, James ^b  

^a PharmaB LLC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Accumulation; CAD; Phospholipid; Phospholipidosis; PLD

Indexed keywords

EID: 80054113467     PISSN: 00657743     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386009-5.00001-1     Document Type: Chapter

References (45)

1. Halliwell W.H. Toxicol. Pathol 1997, 25:53.
2. de la Iglesia F.A., Feuer G., McGuire E.J., Takada A. Toxicol. Appl. Pharmacol. 1977, 34:28.
3. Kodavanti U.P., Mehendale H.M. Pharmacol. Rev. 1990, 42:327.
4. Sawada H., Takami K., Asahi S. Toxicol. Sci. 2005, 83:282.
5. Wilson B.D., Clarkson C.E., Lippman M.L. Am. Rev. Resp. Dis. 1991, 143:1110.
6. Reasor M.J., Hastings K.L., Ulrich R.G. Expert Opin. Drug Saf. 2006, 5:567.
7. Cartwright M.E., Petruska J., Arezzo J., Frank D., Litwak M., Morrissey R.E., MacDonald J., Davis T.E. Toxicol. Pathol. 2009, 37:902.
8. Tengstrand E.A., Miwa G.T., Hsieh F.Y. Expert Opin. Drug Metab. Toxicol. 2010, 6:555.
9. Pink Sheet: August 16, 2004 | Volume 66| Number 033 |p. 24: FDA Phospholipidosis Guidance Being Developed.
10. For slides presented at the FDA PS&CP Advisory Committee meeting on April 14th 2010, see. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210798.pdf.
11. Barone L., Boyer S., Damewood J., Fikes J., Matis S., Gipson G., Ciaccio P. Are Phospholipogenic Compounds Associated with More Toxicities than Non-Phospholipogenic Compounds? 2009.
12. Willard J.M. FDA PLWG Activities on Phospholipidosis: Data Mining, Modeling and Laboratory Research 2010, see Ref.[ 10] for slide set.
13. Small B.G., Barone L.R., Valentine J.P., Pollard C., Ciaccio P.J. J. Pharmacol. Toxicol. Methods 2007, 56(2):e70.
14. Barone L.R., Ciaccio P.J., Small B.G., Valentin J.-P., Pollard C.E. 2007.
15. See Slides 77 and 78 in: J. M. Willard, Ref.[12], FDA ACPS meeting, April 14, 2010.
16. Reasor M.J. Overview of Drug Induced Phospholipidosis 2010, see Ref. [10] for slide set.
17. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Toxicol. Pathol. 2007, 35:325.
18. Ratcliffe A.J. Curr. Med. Chem. 2009, 16:2816.
19. Hastings K.L. Phospholipidosis Industry Perspective 2010, see Ref. [10] for slide set.
20. Chatman L.A., Morton D., Johnson T.O., Anway S.D. Toxicol. Pathol. 2009, 37:997.
21. Leeson P.D., Empfield J.R. Ann. Rep. Med. Chem. 2010, 45:393.
22. Monteith D.K., Morgan R.E., Halstead B. Expert Opin. Drug. Metab. Toxicol. 2006, 2:687.
23. Lowe R., Glen R.C., Mitchell J.B.O. Mol. Pharm. 2010, 7:1708.
24. Fisher H., Kansy M., Bur D. Chimia 2000, 54:640.
25. Ploemen J.-P.H.T.M., Kelder J., Hafmans T., van de Sandt H., van Burgsteden J.A., Salemink P.J.M., van Esch E. Exp. Toxicol. Pathol. 2004, 55:347.
26. Pelletier D.J., Gehlhaar D., Tilloy-Ellul A., Johnson T.O., Greene N. J. Chem. Inf. Model. 2007, 47:1196.
27. Kruhlak N.L., Choi S.S., Contrera J.F., Weaver J.L., Willard J.M., Hastings K.L., Sancilio L.F. Toxicol. Mech. Methods 2008, 18:217.
28. Hanumegowda U.M., Yordanova R., Wenke G., Corradi J.P., Regueiro-Ren A., Adams S.P. Chem. Res. Toxicol. 2010, 23:749.
29. Ulrich R.G., Kilgore K.S., Sun E.L., Cramer C.T., Ginsberg L.C. Toxicol. Methods 1991, 1:89.
30. Gum R.J., Hickman D., Fagerland J.A., Heindel M.A., Gagne G.D., Schmidt J.M., Michaelides M.R., Davidsen S.K., Ulrich R.G. Biochem. Pharmacol. 2001, 62:1661.
31. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., Kakinuma C. Toxicol. Sci. 2006, 90:133.
32. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., Ciaccio P.J. Cell Biol. Toxicol. 2006, 22:15.
33. Natalie M., Margino S., Erik H., Annelieke P., Geert V., Philippe V. Toxicol. In Vitro 2009, 23:217.
34. Nioi P., Perry B.K., Wang E.-J., Gu Y.-Z., Snyder R.D. Toxicol. Sci. 2007, 99:162.
35. Peters J.U., Hunziker D., Fischer H., Kansy M., Weber S., Kritter S., Muller A., Wallier A., Ricklin F., Boehringer M., Poli S.M., Csato M., Loeffler B.-M. Bioorg. Med. Chem. Lett. 2004, 14:3575.
36. Berg A.L., Ciaccio P. Compounds Causing Phospholipidosis, Including Effects on the Central Nervous System 2009.
37. Nugiel D.A., Krumrine J.R., Hill D., Damewood J.R., Bernstein P.R., Sobotka-Briner C.D., Liu J., Zacco A., Pierson M.E. J. Med. Chem. 1876, 2010:53.
38. P. R. Bernstein, 3rd RSC/SCI Symposium on GPCRs in Medicinal Chemistry, MSD, Oss, The Netherlands, September 20-22, 2010.
39. Sarmiento R.M.R., Nettekoven M.T., Taylor S., Plancher J.M., Richter H., Roche O. Bioorg. Med. Chem. Lett. 2009, 19:4495.
40. Sun M., Zhao C., Gfesser G.A., Thiffault C., Miller T.R., Marsh K., Wetter J., Curtis M., Faghih R., Esbenshade T.A., Hancock A.A., Cowart M. J. Med. Chem. 2005, 48:6482.
41. Montenez J.P., Van Bambeke F., Piret J., Brasseur R., Tulkens P.M., Mingeot-Leclercq M.P. Toxicol. Appl. Pharmacol. 1999, 156:129.
42. Bonaventure P., Letavic M., Dugovic C., Wilson S., Aluisio L., Pudiak C., Lord B., Mazur C., Kamme F., Nishino S., Carruthers N., Lovenberg T. Biochem. Pharmacol. 2007, 73:1084.
43. Celanire S., Lebon F., Stark H. in The Third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CSN Disorders 2009, 103-166. See discussion pages 114-116:, CRC Press, Boca Raton.
44. Carruthers N.I. (1-[4-(3-Piperidin-1-ylpropoxy)benzyl]piperidine): A Template for the Design of Potent and Selective Non-Imidazole Histamine H3 Receptor Antagonists 2004.
45. Conn P.J., Christopoulos A., Lindsley C.W. Nat. Rev. Drug Discov. 2009, 8:41.